Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA
Medicus Pharma (NASDAQ:MDCX) announced on Monday that it has submitted an optimized Phase 2 clinical study protocol to the US Food and Drug Administration (FDA) for Teverelix, an investigational GnRH antagonist. The study is designed to evaluate the drug's effectiveness in preventing recurrent acute urinary retention (AURr) in men with benign prostatic hyperplasia (BPH) as part of an existing open Investigational New Drug application.
Medicus Pharma SkinJect Phase 2 study data endorsed by independent expert - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined further progress in its Skinject program following the release of Phase 2 topline data, alongside independent validation from a leading dermatology expert. The company's CEO Raza Bokhari said Medicus Pharma is advancing a novel, noninvasive treatment using patent-protected microneedle arrays designed to treat non-melanoma skin diseases, particularly basal cell carcinoma.
Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data
Medicus Pharma (NASDAQ:MDCX) said on Wednesday its Phase 2 study of SkinJect (SKNJCT-003), a doxorubicin-containing microneedle array for nodular basal cell carcinoma (BCC), showed clinically meaningful activity, supporting plans to advance the therapy toward registrational development. “We believe the positive topline results from 200 ug cohort at day 57, support the therapeutic value of SkinJect and establishes the best path forward towards registrational study,” said Dr. Raza Bokhari, executive chairman and CEO of Medicus.
Medicus Pharma highlights independent support for Phase 2 SkinJect results
Medicus Pharma (NASDAQ:MDCX) announced that an independent assessment of its Phase 2 SkinJect study supports the clinical relevance of the data and continued development of the experimental therapy for non-melanoma skin cancer. The evaluation was provided by Dr Babar Rao, principal investigator of the SKNJCT-003 trial, who described the dataset as “clinically meaningful” and supportive of further trials and regulatory engagement.
Medicus Pharma advances SkinJect, Teverelix programs, eyes catalyst-rich 2026
Medicus Pharma (NASDAQ:MDCX) said on Thursday it is entering a “catalyst-rich” 2026 after reporting annual results and highlighting progress across its SkinJect and Teverelix programs, alongside expansion into precision medicine and AI-enabled clinical development. The clinical-stage biotech said 2025 marked a pivotal year, driven by completion of a Phase 2 study for SkinJect and efforts to broaden its pipeline into rare diseases and women's health.
Medicus Pharma CEO discusses promising Phase 2 SkinJect results - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week highlighted encouraging data from its Phase 2 clinical trial evaluating SkinJect, a non-invasive treatment designed to address basal cell carcinoma, the most common form of skin cancer. Speaking to Proactive, chief executive Raza Bokhari said the latest dataset suggests the company's microneedle-based therapy could significantly reduce the need for surgical intervention in many patients.
Medicus Pharma CEO discusses promising Phase 2 SkinJect results - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week highlighted encouraging data from its Phase 2 clinical trial evaluating SkinJect, a non-invasive treatment...
Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer
Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect microneedle therapy showed encouraging results in treating basal cell carcinoma, the most common form of skin cancer. The Medicus Pharma Ltd said the Phase 2 SKNJCT-003 study evaluating its SkinJect microneedle delivery system achieved 73% clinical clearance and 40% histological clearance in patients treated with a 200-microgram dose by Day 57, the strongest treatment response seen in the trial.
Medicus Pharma CEO discusses Phase 2 skin cancer results - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Dr. Raza Bokhari talked with Proactive about the company's newly reported topline Phase 2 results for its microneedle array patch technology targeting basal cell carcinoma, a common form of non-melanoma skin cancer.
Medicus Pharma reports positive Phase 2 results for microneedle treatment for basal cell carcinoma
Medicus Pharma (NASDAQ:MDCX) said on Thursday that its experimental microneedle-based therapy showed encouraging efficacy in a mid-stage clinical trial for treating Basal Cell Carcinoma, with the highest-dose group achieving 73% clinical clearance of lesions. The Phase 2 randomized, double-blind, placebo-controlled study enrolled 90 patients with nodular basal cell carcinoma and evaluated two doses of the company's doxorubicin microneedle array (D-MNA), a non-invasive treatment designed to deliver chemotherapy through the skin.
Medicus Pharma's Teverelix Phase 2b trial cleared by FDA - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the FDA's clearance to begin a Phase 2b dose optimization study for Teverelix, the company's next-generation GnRH antagonist targeting advanced prostate cancer. Proactive: All right.
Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cacner study
Medicus Pharma (NASDAQ:MDCX) announced that it has received “study may proceed” clearance from the US Food and Drug Administration (FDA) to initiate a Phase 2b dose-optimization study of Teverelix, its investigational long-acting gonadotropin-releasing hormone (GnRH) antagonist, in men with advanced prostate cancer and elevated cardiovascular risk. The open-label Phase 2b trial is expected to enroll 40 patients who are candidates for androgen deprivation therapy.
